TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03799237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GOS trap and dengue NS1 antigen kit
Description: The GOS trap lure and sticky surfaces to trap gravid Aedes mosquitoes. Three GOS traps will be placed on every 3 floors of the residential blocks. The traps will be changed weekly. Trapped Aedes mosquitoes will be identified to species. The mosquitoes will then be dissected, to remove the abdomen from the thorax. Five to seven abdomens of the same mosquito species will be pooled and tested for dengue NS1 antigen using the SD Biosensor Standard Q dengue NS1 antigen test kit. If the pool is tested positive for dengue NS1, the head and thorax of the respective abdomens will be subjected to the same procedure for dengue NS1 antigen test, individually. This may allow us to identify a focus where there could be dengue-infected individuals. Flyers/Posters will be disseminated besides, house-to-house approach to inform the residents of the findings and apartment blocks where these mosquitoes were found. The apartment management will also make use of social media disseminate this information.
Study: NCT04136509

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus floor elevation
Description: sinus floor elevation with the lateral technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus floor elevation
Description: sinus floor elevation with the lateral technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone core biopsy
Description: After 6 month healing time reentry took place and bone core biopsy samples were collected from the augmented bone of the maxillary sinuses with a trephine drill. Biopsy samples were collected from the sites where the dental implants were to be placed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone core biopsy
Description: After 6 month healing time reentry took place and bone core biopsy samples were collected from the augmented bone of the maxillary sinuses with a trephine drill. Biopsy samples were collected from the sites where the dental implants were to be placed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental implant placement
Description: During reentry after bone biopsy dental implants were placed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental implant placement
Description: During reentry after bone biopsy dental implants were placed.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cone Beam Computed Tomography scans (CBCT)
Description: Preoperative CBCT scans are carried out before dental implant placement, 6 months after sinus floor elevations. Postoperative CBCT scans are taken 3 years after sinus floor augmentations.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cone Beam Computed Tomography scans (CBCT)
Description: Preoperative CBCT scans are carried out before dental implant placement, 6 months after sinus floor elevations. Postoperative CBCT scans are taken 3 years after sinus floor augmentations.
Study: NCT03894618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-279252
Description: The investigational product (IP), SL-279252, is a first-in-class agonist redirected checkpoint (ARC) fusion protein (FP) consisting of the extracellular domains of human programmed cell death 1 (PD- 1) and OX40L, linked by a central Fc domain (PD1-Fc-OX40L).
Study: NCT02931552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nuevo Amancer-II Stress Management Program
Description: Participant meets weekly with a trained interventionist called a Compañera (a peer who has had breast cancer) to complete a structured 10-week program designed to develop cognitive and behavioral skills to manage stress and distress, improve communication with family and clinicians, and increase knowledge of self-management after breast cancer.
Study: NCT00799903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darapladib
Description: Lp-PLA2 inhibitor administered in addition to standard therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered in addition to standard therapy
Study: NCT00755495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon and doxepin
Description: Ramelteon 8 mg, tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg, tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxepin
Description: Ramelteon placebo-matching tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
Study: NCT05143034

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TCI66207 Essence
Description: Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Essence
Description: Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.
Study: NCT03551626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Supplied as dabrafenib 50 mg and 75 mg capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Supplied as trametinib 0.5mg, and 2.0mg tablets for oral administration
Study: NCT04438395

Intervention type: DEVICE
Intervention: Cardiac ablation via catheter
Description: Cardiac ablation with a catheter to treat atrial flutter and/or atrial fibrillation
Study: NCT02896283

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: Low-level laser therapy with the following parameters: Wavelength:660 nanometer, power: 200 mW, continuous mode, tme of irradiation: 32 seconds

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Turned-off laser
Description: Laser device is turned-off. All parameters are like experimental group, however the laser in turned-off.
Study: NCT02058446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine/Valsartan
Description: Amlodipine/Valsartan: 5 mg/80 mg
Study: NCT01646086

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12 month behavioral weight loss intervention
Description: The intervention for all groups will follow a standard behavioral weight loss protocol. Participants will meet in groups of up to 20 persons; groups will meet weekly for the first six months, then biweekly for two months and monthly for the remaining four months of the 12-month treatment period. Session content will be centered on behavioral goal setting and attention to caloric intake and physical activity. Participants will be asked to keep daily diet and physical activity logs.
Study: NCT03597516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-G28
Description: powder for reconstitution for oral administration
Study: NCT03461393

Intervention type: DEVICE
Intervention: Medical-Eye-Trainer (MET)
Description: In order to provide a high contrast, dynamic visual stimulus to the patients, we developed an app that allowed the patients to regularly train with this stimulus. The app runs on Android (version 4.2 or later). The display of the screen is divided into 4 rows. In each row, a pattern of black and white squares is moving in one direction. The directions in subsequent rows are opposite to each other. Through the movement in the opposite direction a changing pattern is achieved in vertical and horizontal extension, the pattern alternates between continuous beams and a checkered pattern. The speed of the display on the monitor is 2 cm per second. In a comfortable viewing distance (ca. 40 cm), this leads to an angular velocity of approximately 3°/sec.
Study: NCT02575261

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cell immunotherapy
Description: This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EphA2 antigen.
Study: NCT01646086

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12 month behavioral weight loss intervention
Description: The intervention for all groups will follow a standard behavioral weight loss protocol. Participants will meet in groups of up to 20 persons; groups will meet weekly for the first six months, then biweekly for two months and monthly for the remaining four months of the 12-month treatment period. Session content will be centered on behavioral goal setting and attention to caloric intake and physical activity. Participants will be asked to keep daily diet and physical activity logs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12 month behavioral weight loss intervention
Description: The intervention for all groups will follow a standard behavioral weight loss protocol. Participants will meet in groups of up to 20 persons; groups will meet weekly for the first six months, then biweekly for two months and monthly for the remaining four months of the 12-month treatment period. Session content will be centered on behavioral goal setting and attention to caloric intake and physical activity. Participants will be asked to keep daily diet and physical activity logs.
Study: NCT02175017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: ONO-4538 Study in Patients With Squamous NSCLC
Study: NCT03386630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine+Sufentanil
Description: To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: sufentanil (5 mcg)
Study: NCT03597516

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: powder for reconstitution for oral administration
Study: NCT01755416

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Closed loop with sensor and Insulin
Description: Subject will be on the closed loop device with enlite sensors for about 27 hours. They will not be on any study medication and will be on insulin alone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Closed loop with sensor, Insulin and Liraglutide
Description: In this study visit the subject will be on the closed loop device with enlite sensors for about 27 hours. In addition to being on insulin, they would take a single injection of 1.2 mg of Liraglutide subcutaneously before dinner on Day 1.
Study: NCT02696551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical education
Study: NCT00445328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin (Fragmin)
Description: Dalteparin 5000 IU once daily subcutaneously for 6-14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Unfractionated heparin 5000 IU thrice daily subcutaneously for 6-14 days.
Study: NCT03386630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine+Morphine
Description: To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: morphine (0,01 mg)
Study: NCT04056650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-theanine
Description: up to 250 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine supplement
Description: 50-400mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine supplement
Description: 50-400mg

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N1 app
Description: N1 App on mobile device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N1 app
Description: N1 App on mobile device
Study: NCT04683185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6742
Description: E6742 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6742
Description: E6742 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6742
Description: E6742 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E6742-matched placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E6742-matched placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E6742-matched placebo tablets.
Study: NCT02175017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: ONO-4538 Study in Patients With Non-Squamous NSCLC
Study: NCT04291859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF28996
Description: capsule, orally, doses and dose escalation scheme will be decided upon at dosing conferences
Study: NCT01345188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranexa
Description: 1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
Study: NCT03214354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab, Day -7 to -3. Dose: 0.2mg/kg/dose SC once daily x 5 days
Study: NCT03014726

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Urotronic Drug Coated Balloon (DCB)
Description: Urotronic Drug Coated Balloon (DCB) is a catheter with a tapered atraumatic tip. The distal end of the catheter has a semi-compliant inflatable balloon coated with a proprietary coating containing the drug and carriers.
Study: NCT01761565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of SUF NT 15 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes
Study: NCT00581334

Intervention type: PROCEDURE
Intervention: Robotic-assisted laparoscopic sacrocolpopexy
Description: 4 abdominal incisions will be made: 1 infraumbilical port and 3 lateral ports. The peritoneum overlaying the sacrum is entered and the anterior longitudinal ligament is exposed. 3 permanent sutures are placed through the ligament at the S2-S3. Then a vaginal obturator is placed transvaginally and the apex of vagina is elevated into the operative field. The peritoneum overlying the anterior and posterior vaginal epithelium is reflected and the bladder is dissected off the underlying vagina to expose 4cm of apical vagina. 2 segments of polypropylene mesh are prepared and one segment is anchored along the anterior vagina with a series of interrupted permanent suture and the second segment is anchored along the posterior vagina. These 2 segments are brought together to the previously placed sutures within the anterior longitudinal ligament of the sacrum. The peritoneum is then closed over the graft complex and the pelvis irrigated. The 4 robotic ports are removed and the abdomen closed.

Intervention type: PROCEDURE
Intervention: Open sacrocolpopexy
Description: mesh augmented repair for post-hysterectomy prolapse performed via open laparotomy
Study: NCT00137306

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Facilitate evidence-based treatment for depression
Study: NCT03995758

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MOSES
Description: software based modulation of the laser energy delivered from the homium laser source. The software changes the pulsed laser to have two peaks of energy - one to displace water in front of the stone and a second to deliver the laser energy to the stone

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MOSES
Description: software based modulation of the laser energy delivered from the homium laser source. The software changes the pulsed laser to have two peaks of energy - one to displace water in front of the stone and a second to deliver the laser energy to the stone
Study: NCT03214354

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: TBI 300 cGy on Day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus is used for GVHD prophylaxis
Study: NCT03532126

Intervention type: DEVICE
Intervention: Dermal filler for midface deficit
Description: During this procedure the device (a dermal filler) will be deep intradermal, subcutaneous or supraperiosteal injected according to its CE mark.
Study: NCT04724915

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Total Knee Arthroplasty
Description: People will undergo surgery to replace the knee joint with a prosthesis in case of osteoarthritis. This will be performed with manual instrumentarium (jig-based).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Total Knee Arthroplasty
Description: People will undergo surgery to replace the knee joint with a prosthesis in case of osteoarthritis. This will be performed with the help of a surgical robot.
Study: NCT03292068

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Acupuncture, acupressure
Description: Intervention group will receive usual care in combination with Pyonex-needles and Kulplåster. The control group will only receive usual care.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Timbal diet
Description: Intervention group will receive usual care in combination Timbal diet including Protein-enriched ice cream, made with egg yolks and Cream. The control group will only receive usual care.

Intervention type: OTHER
Group type: OTHER
Intervention: Extended telephone counseling
Description: Intervention group will receive usual care in combination with Extended telephone counseling. The control group will only receive usual care.
Study: NCT00882323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Fludarabine, Thymoglobulin
Description: cyclophosphamide (60 mg/kg once daily i.v. on days -8, -7)~fludarabine (40 mg/m2 once daily i.v. on days -6, -5, -4, -3, -2)~thymoglobulin (2.5 mg/kg once daily i.v. on days -4, -3, -2)
Study: NCT02067936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A propofol + remifentanil
Description: Predicted TOL90% according to Bouillon model

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group B propofol + remifentanil
Description: TOL 90% according to the Bouillon interaction model

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group C propofol + remifentanil
Description: TOL 90% according to the Bouillon interaction model

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group D propofol + remifentanil
Description: TOL 90% according to the Bouillon interaction model
Study: NCT03305770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: verofilcon A contact lenses
Description: Daily disposable soft contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: delefilcon A contact lenses
Description: Daily disposable soft contact lenses
Study: NCT01067144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lorazepam (active control)
Description: 0.5 mg Lorazepam (active control) given pre-operatively in a single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (inactive)
Description: 2 capsules of inactive placebo given 3-times a day post-operatively for the 72-hour post-surgical period.
Study: NCT01444885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 weeks treatment of Cilostazol 100mg, or placebo oral tablets bid after 2 weeks treatment of Cilostazol 50mg, or placebo oral tablets bid (Total 4 weeks)
Study: NCT01026441

Intervention type: DEVICE
Group type: OTHER
Intervention: Vela100 (Aesthetic)
Description: 6 treatments once a week
Study: NCT02267122

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ionic silver-containing dressing
Description: After placing the staples, a ionic silver-containing dressing was placed covering the wound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mupirocin ointment application
Description: After placing the staples, Mupirocin ointment application over the wound was performed
Study: NCT03778788

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: App group
Description: Intervention group the participants will receive a Lifestyle Intervention Program (LIP) with the support of MetS mobile application (MetS app). The MetS app support include app installment and briefing by a research assistant after the educational talk. The participants can view the similar knowledge content related to metabolic syndrome in their own smart phone. In addition, a membership area provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the briefing.
Study: NCT00287716

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: 1197 or 2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: 1197 or 2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
Study: NCT00924248

Intervention type: DRUG
Intervention: Gadoxetic acid disodium (Primovist, BAY86-4873)
Description: Patients in daily life clinical practice treatment receiving Primovist according to indication on the label.
Study: NCT00982826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-072
Description: See Arms information for a detailed description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-072
Description: See Arms information for a detailed description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-072
Description: See Arms information for a detailed description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-072
Description: See Arms information for a detailed description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See Arms information for a detailed description.